{Reference Type}: Case Reports
{Title}: Long-term remission following esketamine nasal spray sessions in a patient with severe and highly treatment-resistant depression: a single-case report.
{Author}: Arrighi L;Maakaron E;Korchia T;Lançon C;Richieri R;
{Journal}: Int Clin Psychopharmacol
{Volume}: 39
{Issue}: 5
{Year}: 2024 Sep 1
{Factor}: 2.023
{DOI}: 10.1097/YIC.0000000000000482
{Abstract}: About 30% of patients with major depressive disorder have treatment-resistant depression (TRD). Recently, intranasal esketamine was approved as a treatment option after the failure of two antidepressant trials. We report a patient with multiresistant depression that was successfully and safely treated with esketamine nasal spray. This 31-year-old inpatient with severe, chronic, and multi-TRD received an acute course of intranasal esketamine (84 mg). Previously, 14 different antidepressants, alone or in potentiation, and several neurostimulation techniques had been unsuccessful. Over 20 bi-weekly sessions, she had no significant adverse effects and was stabilized into remission. During the maintenance phase and 1 year after, she continues to be stable. This case report provides an example of a patient with severe TRD that showed significant improvement after treatment with intranasal esketamine.